A drug put into the brain fluid for lung cancer that spread to the brain lining
Original title: Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, so we do not know yet if it helps.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests thiotepa, a drug placed right into the fluid around the brain.
Who this trial is for. This is for people with non-small cell lung cancer that spread to the lining of the brain. Their cancer no longer responds to targeted drugs called EGFR-TKI. The trial tests thiotepa given through an Ommaya reservoir, a small device that reaches the brain fluid.
Where it stands. The trial has not reported results. It is measuring if the drug is safe to inject this way. It is also measuring how well it controls the cancer in the head. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone whose situation fits this could ask their care team about it. Doctors want to learn if giving thiotepa this way is safe and helpful.
What it doesn't mean: This does not mean thiotepa works for this cancer. A trial is a test, not a proven treatment. Being in one does not promise that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.